BSGM vs. SIBN, IRMD, CBLL, BBNX, AVNS, EMBC, BVS, KIDS, RXST, and BFLY
Should you be buying Biosig Technologies stock or one of its competitors? The main competitors of Biosig Technologies include SiBone (SIBN), iRadimed (IRMD), CeriBell (CBLL), Beta Bionics (BBNX), Avanos Medical (AVNS), Embecta (EMBC), Bioventus (BVS), OrthoPediatrics (KIDS), RxSight (RXST), and Butterfly Network (BFLY). These companies are all part of the "medical equipment" industry.
Biosig Technologies vs. Its Competitors
Biosig Technologies (NASDAQ:BSGM) and SiBone (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.
In the previous week, Biosig Technologies had 2 more articles in the media than SiBone. MarketBeat recorded 3 mentions for Biosig Technologies and 1 mentions for SiBone. SiBone's average media sentiment score of 1.89 beat Biosig Technologies' score of 0.91 indicating that SiBone is being referred to more favorably in the news media.
7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 17.0% of Biosig Technologies shares are owned by company insiders. Comparatively, 4.0% of SiBone shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Biosig Technologies has higher earnings, but lower revenue than SiBone.
Biosig Technologies has a net margin of 0.00% compared to SiBone's net margin of -15.03%. SiBone's return on equity of -16.00% beat Biosig Technologies' return on equity.
Biosig Technologies has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Comparatively, SiBone has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.
Biosig Technologies currently has a consensus target price of $10.00, suggesting a potential downside of 2.30%. SiBone has a consensus target price of $22.50, suggesting a potential upside of 21.89%. Given SiBone's higher possible upside, analysts clearly believe SiBone is more favorable than Biosig Technologies.
Summary
SiBone beats Biosig Technologies on 7 of the 13 factors compared between the two stocks.
Get Biosig Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for BSGM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BSGM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biosig Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:BSGM) was last updated on 7/3/2025 by MarketBeat.com Staff
Free BSGM Stock Alerts